| Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors AB Apolo, R Nadal, DM Girardi, SA Niglio, L Ley, LM Cordes, ... Journal of Clinical Oncology 38 (31), 3672-3684, 2020 | 109 | 2020 |
| Impact of surgical margin status on prostate‐cancer‐specific mortality HJ Chalfin, M Dinizo, BJ Trock, Z Feng, AW Partin, PC Walsh, ... BJU international 110 (11), 1684-1689, 2012 | 104 | 2012 |
| Hospital charges and length of stay following radical cystectomy in the enhanced recovery after surgery era A Semerjian, N Milbar, M Kates, MA Gorin, HD Patel, HJ Chalfin, ... Urology 111, 86-91, 2018 | 77 | 2018 |
| The relationship between the extent of extraprostatic extension and survival following radical prostatectomy BC Jeong, HJ Chalfin, SB Lee, Z Feng, JI Epstein, BJ Trock, AW Partin, ... European urology 67 (2), 342-346, 2015 | 67 | 2015 |
| New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8–10 prostate cancer WS Ham, HJ Chalfin, Z Feng, BJ Trock, JI Epstein, C Cheung, ... European urology 71 (6), 907-912, 2017 | 61 | 2017 |
| Obesity and long-term survival after radical prostatectomy HJ Chalfin, SB Lee, BC Jeong, SJ Freedland, H Alai, Z Feng, BJ Trock, ... The Journal of urology 192 (4), 1100-1104, 2014 | 53 | 2014 |
| Variability in medicare utilization and payment among urologists JS Ko, H Chalfin, BJ Trock, Z Feng, E Humphreys, SW Park, HB Carter, ... Urology 85 (5), 1045-1051, 2015 | 48 | 2015 |
| Blood transfusion is associated with increased perioperative morbidity and adverse oncologic outcomes in bladder cancer patients receiving neoadjuvant chemotherapy and radical … HJ Chalfin, JJ Liu, N Gandhi, Z Feng, D Johnson, GJ Netto, CG Drake, ... Annals of surgical oncology 23, 2715-2722, 2016 | 41 | 2016 |
| Allogeneic versus autologous blood transfusion and survival after radical prostatectomy (CME) HJ Chalfin, SM Frank, Z Feng, BJ Trock, CG Drake, AW Partin, ... Transfusion 54 (9), 2168-2174, 2014 | 39 | 2014 |
| Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer HJ Chalfin, SA Glavaris, MA Gorin, MR Kates, MH Fong, L Dong, ... European urology oncology 4 (2), 310-314, 2021 | 35 | 2021 |
| Circulating tumor cell subtypes and T-cell populations as prognostic biomarkers to combination immunotherapy in patients with metastatic genitourinary cancer HJ Chalfin, T Pramparo, A Mortazavi, SA Niglio, JD Schonhoft, ... Clinical Cancer Research 27 (5), 1391-1398, 2021 | 26 | 2021 |
| Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic … EE van der Toom, VP Groot, SA Glavaris, G Gemenetzis, HJ Chalfin, ... The Prostate 78 (4), 300-307, 2018 | 24 | 2018 |
| Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell … HJ Chalfin, SA Glavaris, PD Malihi, JM Sperger, MA Gorin, C Lu, ... The Journal of urology 199 (6), 1494-1501, 2018 | 22 | 2018 |
| Characterization of urothelial cancer circulating tumor cells with a novel selection-free method HJ Chalfin, M Kates, EE van der Toom, S Glavaris, JE Verdone, NM Hahn, ... Urology 115, 82-86, 2018 | 20 | 2018 |
| Nucleolin staining may aid in the identification of circulating prostate cancer cells HJ Chalfin, JE Verdone, EE van der Toom, S Glavaris, MA Gorin, ... Clinical genitourinary cancer 15 (3), e477-e481, 2017 | 20 | 2017 |
| Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer AC Civelek, SA Niglio, AA Malayeri, J Lin, S Gurram, HJ Chalfin, ... Urologic Oncology: Seminars and Original Investigations 39 (11), 787. e17 …, 2021 | 19 | 2021 |
| Thrombosis risk in cancer patients receiving red blood cell transfusions G Ramsey, PF Lindholm Seminars in thrombosis and hemostasis 45 (06), 648-656, 2019 | 18 | 2019 |
| Improving prostate cancer screening and diagnosis: health policy and biomarkers beyond PSA HD Patel, HJ Chalfin, HB Carter JAMA oncology 2 (7), 867-868, 2016 | 17 | 2016 |
| Cabozantinib plus nivolumab phase I expansion study in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitor therapy DM Girardi, SA Niglio, A Mortazavi, R Nadal, P Lara, SK Pal, B Saraiya, ... Clinical Cancer Research 28 (7), 1353-1362, 2022 | 15 | 2022 |
| Robotic primary RPLND for stage I testicular cancer: a review of indications and outcomes HJ Chalfin, W Ludwig, PM Pierorazio, ME Allaf Current urology reports 17, 1-6, 2016 | 14 | 2016 |
Misop HanProfessor of Urology在 jhmi.edu 的电子邮件经过验证
